Literature DB >> 22393079

Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response.

Deborah L White, Timothy P Hughes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22393079     DOI： 10.1200/JCO.2011.41.1090

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

Authors:  Anne T Nies; Elke Schaeffeler; Heiko van der Kuip; Ingolf Cascorbi; Oliver Bruhn; Michael Kneba; Christiane Pott; Ute Hofmann; Christopher Volk; Shuiying Hu; Sharyn D Baker; Alex Sparreboom; Peter Ruth; Hermann Koepsell; Matthias Schwab
Journal:  Clin Cancer Res       Date:  2013-12-18       Impact factor: 12.531

Review 2.  OCT1 and imatinib transport in CML: is it clinically relevant?

Authors:  D B Watkins; T P Hughes; D L White
Journal:  Leukemia       Date:  2015-07-09       Impact factor: 11.528

3.  Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells.

Authors:  J Wang; T P Hughes; C H Kok; V A Saunders; A Frede; K Groot-Obbink; M Osborn; A A Somogyi; R J D'Andrea; D L White
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

4.  Predictive Value of Pretreatment BCR-ABL(IS) Transcript level on Response to Imatinib Therapy in Egyptian Patients with Chronic Phase Chronic Myeloid Leukemia (CPCML).

Authors:  Wafaa H El-Metnawy; Mervat M Mattar; Yasser H El-Nahass; Mohamed A Samra; Hala M Abdelhamid; Raafat M Abdlfattah; Ahmad R Hamed
Journal:  Int J Biomed Sci       Date:  2013-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.